AQUINOX PHARMACEUTICALS, INC (26)
Browse by Contract Category
Contracts
-
Forms of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice for Registrants 2014 Equity Incentive Plan
(Filed With SEC on August 12, 2020)
-
First Amendment, dated June 18, 2020, to Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC
(Filed With SEC on August 12, 2020)
-
Form of Pre-Funded Warrant
(Filed With SEC on July 2, 2020)
-
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended
(Filed With SEC on March 12, 2020)
-
Exclusive Start-Up License Agreement, dated July 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc
(Filed With SEC on August 12, 2019)
-
Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August 5, 2019
(Filed With SEC on August 6, 2019)
-
Early Termination Agreement by and between Aquinox Pharmaceuticals (Canada), Inc. and Astellas US LLC, effective as of November 8, 2018
(Filed With SEC on March 7, 2019)
-
Underwriting Agreement, dated July 1, 2020
(Filed With SEC on July 2, 2020)
-
Neoleukin Therapeutics, Inc. 2020 Employee Stock Purchase Plan
(Filed With SEC on May 6, 2020)
-
Employment Agreement, dated March 16, 2020, by and between Neoleukin Therapeutics, Inc. and Robert Ho
(Filed With SEC on May 6, 2020)
-
Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G. Drachman
(Filed With SEC on April 17, 2020)
-
Lease Agreement, dated December 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC
(Filed With SEC on March 12, 2020)
-
Underwriting Agreement, dated December 17, 2019
(Filed With SEC on December 19, 2019)
-
Exchange Agreement, dated December 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P
(Filed With SEC on December 19, 2019)
-
Form of Pre-Funded Warrant
(Filed With SEC on December 19, 2019)
-
Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan, as amended November 12, 2019
(Filed With SEC on November 14, 2019)
-
Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC
(Filed With SEC on November 13, 2019)
-
Amendment No. 1 to the Facility Use Agreement, dated April 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc
(Filed With SEC on August 12, 2019)
-
Facility Use Agreement, dated December 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc
(Filed With SEC on August 12, 2019)
-
Transition Retention Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamram Alam
(Filed With SEC on August 6, 2019)
-
Employment Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Jonathan G. Drachman
(Filed With SEC on August 6, 2019)
-
Separation Agreement and Release, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J. Main
(Filed With SEC on August 6, 2019)
-
Form of Lock-Up Agreement, by each of the parties named in each agreement therein
(Filed With SEC on August 6, 2019)
-
Form of Support Agreement, by and among Aquinox Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc. and each of the parties named in each agreement therein
(Filed With SEC on August 6, 2019)
-
Executive Employment Agreement Amendment for David Main
(Filed With SEC on August 1, 2019)
-
Executive Employment Agreement Amendment for Kamran Alam
(Filed With SEC on August 1, 2019)